中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 8
Aug.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(8): 1598-1604

Primary biliary cholangitis with metabolic associated fatty liver disease： Clinical features and risk factors

DOI: 10.12449/JCH240815
  • 1.

    Department of Psychiatry ‍I‍，Yunnan Provincial Hospital of Infectious Diseases/Yunnan Mental Health Center，Anning，Yunnan 650302，China

  • 2.

    Department of Infection and Liver Diseases，The First Affiliated Hospital of Kunming Medical University，Kunming 650032，China

Research funding:

National Natural Science Foundation of China (82160801);

Yunnan Province Famous Doctor Project (Yunrenweifa（2020）20);

Yunnan Province Famous Doctor Project (RLMY20200015);

Yunnan Provincial Department of Science and Technology-Applied Basic Research Joint Special Fund Project (2018FE001（-214）)

More Information
  • Corresponding author: LI Wu， liwukm@qq.com （ORCID： 0000-0002-1222-3629）
  • Received Date: 2023-04-22
  • Accepted Date: 2023-05-18
  • Published Date: 2024-08-25
    Abstract
  •   Objective  To investigate the clinical features and risk factors of primary biliary cholangitis （PBC） comorbid with metabolic associated fatty liver disease （MAFLD） and the interaction between the two diseases.  Methods  A total of 187 patients who were diagnosed with PBC， MAFLD， or PBC with MAFLD in The First Affiliated Hospital of Kunming Medical University from January 2019 to December 2022 were enrolled and divided into PBC group with 70 patients， PBC+MAFLD group with 38 patients， and MAFLD group with 79 patients. Related data were collected， including general information， clinical symptoms， serological parameters， transient elastography （FibroScan）， and non-invasive fibrosis markers， which were compared between the three groups. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups， the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups， and the binary Logistic regression analysis was used for multivariate analysis.  Results  There were significant differences between the three groups in sex， age， height， weight， body mass index （BMI）， and history of autoimmune diseases （P<0.05）. In the PBC+MAFLD group， female patients accounted for 89.5%， with a mean age of 57.26±12.72 years and a BMI of 23.35±3.70 kg/m2， and in the PBC group， the detection rate of autoimmune diseases was 25.7% （18 patients）. There were significant differences between the three groups in the incidence rates of weakness， poor appetite， pruritus， jaundice， varices， ascites， and splenomegaly （all P<0.05）. The PBC+MAFLD group had the common symptoms of weakness in 18 patients （47.4%）， poor appetite in 15 patients （39.5%）， abdominal pain in 14 patients （36.8%）， and abdominal distension in 16 patients （42.1%）； the MAFLD group had the common symptoms of abdominal pain in 34 patients （43%） and abdominal distension in 32 patients （40.5%）； the PBC group had the common symptoms of weakness in 37 patients （52.9%）， poor appetite in 25 patients （35.7%）， jaundice in 25 patients （35.7%）， abdominal pain in 18 patients （25.7%）， abdominal distension in 25 patients （35.7%）， varices in 19 patients （27.9%）， ascites in 23 patients （32.9%）， and splenomegaly in 44 patients （62.9%）. The PBC+MAFLD group had a controlled attenuation parameter （CAP）， which was higher than that of the PBC group， and the PBC group had significantly higher levels of liver stiffness measurement， aspartate aminotransferase-to-platelet ratio index （APRI）， and fibrosis-4 （FIB-4） than the MAFLD group （all P<0.05）. The factors without multicollinearity were included in the regression analysis， and with the PBC group as the reference group， FIB-4 （odds ratio ［OR］=0.218， 95% confidence interval ［CI］： 0.069 ‍—‍ 0.633， P<0.05） and history of autoimmune diseases （OR=0.229， 95%CI： 0.067‍ — ‍0.810， P<0.05） were influencing factors for the onset of PBC with MAFLD； with the MAFLD group as the reference group， ALT （OR=0.157， 95%CI： 0.025‍ —‍ ‍1.000， P<0.05） and TBil （OR=0.995， 95%CI： 0.990‍‍ — ‍0.999， P<0.05） were influencing factors for the onset of PBC with MAFLD.  Conclusion  PBC with MAFLD lacks specific clinical manifestations， and PBC patients tend to have more severe clinical manifestations and a higher incidence rate of liver function decompensation. PBC comorbid with MAFLD may not aggravate the disease progression of PBC.

     

    • FullText(HTML)
    • References(27)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 35- 41.

    中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 35- 41.
    [2]
    XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36( 6): 1224- 1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.

    薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36( 6): 1224- 1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007
    [3]
    BRUNT EM, RAMRAKHIANI S, CORDES BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease[J]. Mod Pathol, 2003, 16( 1): 49- 56. DOI: 10.1097/01.MP.0000042420.21088.C7.
    [4]
    JEFFERY ND, HAMILTON L, GRANGER N. Designing clinical trials in canine spinal cord injury as a model to translate successful laboratory interventions into clinical practice[J]. Vet Rec, 2011, 168( 4): 102- 107. DOI: 10.1136/vr.d475.
    [5]
    SEIKE T, KOMURA T, SHIMIZU Y, et al. A young man with non-alcoholic steatohepatitis and serum anti-mitochondrial antibody positivity[J]. Intern Med, 2018, 57( 21): 3093- 3097. DOI: 10.2169/internalmedicine.0405-17.
    [6]
    ESLAM M, SARIN SK, WONG VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14( 6): 889- 919. DOI: 10.1007/s12072-020-10094-2.
    [7]
    ILUZ-FREUNDLICH D, UHANOVA J, GRUBERT VAN IDERSTINE M, et al. The impact of primary biliary cholangitis on non-alcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2021, 33( 4): 565- 570. DOI: 10.1097/MEG.0000000000001782.
    [8]
    LAN RY, CHENG CM, LIAN ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis[J]. Hepatology, 2006, 43( 4): 729- 737. DOI: 10.1002/hep.21123.
    [9]
    SÖDERBERG C, MARMUR J, ECKES K, et al. Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis[J]. APMIS, 2011, 119( 7): 412- 420. DOI: 10.1111/j.1600-0463.2011.02746.x.
    [10]
    ODIN JA, HUEBERT RC, CASCIOLA-ROSEN L, et al. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis[J]. J Clin Invest, 2001, 108( 2): 223- 232. DOI: 10.1172/JCI10716.
    [11]
    MA C, KESARWALA AH, EGGERT T, et al. NAFLD causes selective CD4(+‍) T lymphocyte loss and promotes hepatocarcinogenesis[J]. Nature, 2016, 531( 7593): 253- 257. DOI: 10.1038/nature16969.
    [12]
    HÍNDI M, LEVY C, COUTO CA, et al. Primary biliary cirrhosis is more severe in overweight patients[J]. J Clin Gastroenterol, 2013, 47( 3): e28- e32. DOI: 10.1097/MCG.0b013e318261e659.
    [13]
    FRIEDRICH-RUST M, MÜLLER C, WINCKLER A, et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers[J]. J Clin Gastroenterol, 2010, 44( 1): 58- 65. DOI: 10.1097/MCG.0b013e3181a84b8d.
    [14]
    SORRENTINO P, TERRACCIANO L, D’ANGELO S, et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis[J]. J Gastroenterol, 2010, 45( 10): 1053- 1062. DOI: 10.1007/s00535-010-0249-x.
    [15]
    BERZIGOTTI A, GARCIA-TSAO G, BOSCH J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis[J]. Hepatology, 2011, 54( 2): 555- 561. DOI: 10.1002/hep.24418.
    [16]
    TSUNEYAMA K, BABA H, KIKUCHI K, et al. Autoimmune features in metabolic liver disease: A single-center experience and review of the literature[J]. Clin Rev Allergy Immunol, 2013, 45( 1): 143- 148. DOI: 10.1007/s12016-013-8383-x.
    [17]
    ALEFFI S, PETRAI I, BERTOLANI C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells[J]. Hepatology, 2005, 42( 6): 1339- 1348. DOI: 10.1002/hep.20965.
    [18]
    MARRA F, BERTOLANI C. Adipokines in liver diseases[J]. Hepatology, 2009, 50( 3): 957- 969. DOI: 10.1002/hep.23046.
    [19]
    ZHANG Y, HU X, CHANG J, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis[J]. BMC Gastroenterol, 2021, 21( 1): 395. DOI: 10.1186/s12876-021-01974-4.
    [20]
    KAZANKOV K, JØRGENSEN SMD, THOMSEN KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 3): 145- 159. DOI: 10.1038/s41575-018-0082-x.
    [21]
    LOAEZA-DEL CASTILLO AM, GAYTÁN-SANTILLÁN A, LÓPEZ-TELLO A, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis[J]. Ann Hepatol, 2019, 18( 6): 879- 882. DOI: 10.1016/j.aohep.2019.07.006.
    [22]
    FRITHIOFF-BØJSØE C, LUND MAV, LAUSTEN-THOMSEN U, et al. Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity[J]. Pediatr Diabetes, 2020, 21( 2): 194- 202. DOI: 10.1111/pedi.12964.
    [23]
    Authors/Task Force Members; ESC Committee for Practice Guidelines(CPG); National Cardiac Societies ESC. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk[J]. Atherosclerosis, 2019, 290: 140- 205. DOI: 10.1016/j.atherosclerosis.2019.08.014.
    [24]
    RESHETNYAK VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis[J]. World J Gastroenterol, 2015, 21( 25): 7683- 7708. DOI: 10.3748/wjg.v21.i25.7683.
    [25]
    LIU WY, XIE DM, ZHU GQ, et al. Targeting fibroblast growth factor 19 in liver disease: A potential biomarker and therapeutic target[J]. Expert Opin Ther Targets, 2015, 19( 5): 675- 685. DOI: 10.1517/14728222.2014.997711.
    [26]
    YANG L, XU LH. Research progress of gut microbiota and primary biliary cholangitis[J]. J Med Postgrad, 2019, 32( 12): 1324- 1328. DOI: 10.16571/j.cnki.1008-8199.2019.12.018.

    杨柳, 徐丽红. 肠道菌群与原发性胆汁性胆管炎的研究进展[J]. 医学研究生学报, 2019, 32( 12): 1324- 1328. DOI: 10.16571/j.cnki.1008-8199.2019.12.018.
    [27]
    LEMOINNE S, KEMGANG A, BELKACEM K BEN, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis[J]. Gut, 2020, 69( 1): 92- 102. DOI: 10.1136/gutjnl-2018-317791.
    • Relative Articles

  • Relative Articles

    [1]Qiupeng WANG, Meifu GAN. Pathological diagnosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1088-1092. doi: 10.12449/JCH240604
    [2]Nan WANG, Rong HU, Shihui BIAN, Wei ZHONG, Pengfei ZHANG, Youwen TAN. Value of alkaline phosphatase level after ursodeoxycholic acid treatment for one month and baseline red blood cell distribution width in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(3): 496-501. doi: 10.12449/JCH240310
    [3]Yingdie ZHU, Zhijiao ZHANG, Guilin ZHANG, Yunkun GAO, Mengyao ZHENG, Hua HUANG, Gongfang ZHAO. Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1591-1597. doi: 10.12449/JCH240814
    [4]Yujie QIN, Wenxiu ZHOU, Xingnian ZHOU, Mingliang CHENG, Hong LI. Report and genetic analysis of autoimmune liver diseases between mother and daughter[J]. Journal of Clinical Hepatology, 2023, 39(2): 387-391. doi: 10.3969/j.issn.1001-5256.2023.02.021
    [5]Zhicheng LIU, Zilong WANG, Jiarui ZHENG, Yandi XIE, Guangjun SONG, Bo FENG. Prevalence of primary biliary cholangitis in the Chinese general population and its influencing factors: A systematic review[J]. Journal of Clinical Hepatology, 2023, 39(2): 325-332. doi: 10.3969/j.issn.1001-5256.2023.02.011
    [6]Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU. Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2817-2823. doi: 10.3969/j.issn.1001-5256.2023.12.011
    [7]Lin HAN, Qingsheng LIANG, Huan XIE, Ying CHEN, Jun ZHAO, Mingyue ZHANG, Baosen LI, Yanli DONG, Ying SUN. Value of baseline IgM level in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(4): 815-820. doi: 10.3969/j.issn.1001-5256.2022.04.015
    [8]Xinhang SONG, Juanhan YU, Zhaoping CHENG, Chen SHAO, Baocheng DENG. Pathological staging systems of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(3): 653-655. doi: 10.3969/j.issn.1001-5256.2022.03.033
    [9]Fang QIU, Chan WANG, Mingming ZHANG, Xingjuan SHI, Xiangdong LIU. Genetic studies of primary biliary cholangitis in the post-GWAS era[J]. Journal of Clinical Hepatology, 2022, 38(4): 759-761. doi: 10.3969/j.issn.1001-5256.2022.04.005
    [10]Xing LYU, Ting LI, Xiaodong SUN, Jianpeng ZHOU, Dongxia WANG, Guoyue LYU. Research advances in the treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 2130-2135. doi: 10.3969/j.issn.1001-5256.2022.09.035
    [11]Haitao MA, Yingmei TANG. Research advances in exosomes in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1896-1900. doi: 10.3969/j.issn.1001-5256.2022.08.035
    [12]Yunxia WU, Chengliang LI, Xiaolei LI, Zhaoxiao LUO, Tianshun REN. Correlation between cardiometabolic index and metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(10): 2247-2251. doi: 10.3969/j.issn.1001-5256.2022.10.010
    [13]Cheng ZHOU, Ran JIA, Jingjing WEI, Chenlu ZHAO, Dongfang SHANG, Wenxia ZHAO. Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2592-2595. doi: 10.3969/j.issn.1001-5256.2022.11.031
    [14]Jingyi ZHANG, Yingmei. TANG. Features and prognosis of Hashimoto's thyroiditis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1521-1528. doi: 10.3969/j.issn.1001-5256.2022.07.013
    [15]Ma WeiYu, Deng ZhiHua. Current status of immunogenetic studies on primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 932-935. doi: 10.3969/j.issn.1001-5256.2020.04.050
    [16]Huang ZhiQin, Huang HuiFang. Research advances in cytokines associated with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(2): 446-450. doi: 10.3969/j.issn.1001-5256.2020.02.047
    [17]Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
    [18]Xu Li, Zheng YueQi, Shi Zhen, Chen YiYun, Shao HuiJiang, Chen JianJie. Influencing factors for the prognosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1870-1873. doi: 10.3969/j.issn.1001-5256.2019.08.050
    [19]Zhang JiYu, Fan XingLiang. Research advances in the mouse model of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2235-2238. doi: 10.3969/j.issn.1001-5256.2017.11.041
    [20]Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040255075100125
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 25.1 %FULLTEXT: 25.1 %META: 66.9 %META: 66.9 %PDF: 7.9 %PDF: 7.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.6 %其他: 7.6 %Lecce: 0.3 %Lecce: 0.3 %Tiruchi: 0.3 %Tiruchi: 0.3 %上海: 1.9 %上海: 1.9 %伦敦: 0.2 %伦敦: 0.2 %保定: 0.3 %保定: 0.3 %加利福尼亚州: 0.2 %加利福尼亚州: 0.2 %北京: 3.7 %北京: 3.7 %南京: 0.3 %南京: 0.3 %南宁: 0.2 %南宁: 0.2 %卡纳塔克: 0.3 %卡纳塔克: 0.3 %呼和浩特: 0.2 %呼和浩特: 0.2 %咸阳: 0.2 %咸阳: 0.2 %哥伦布: 0.8 %哥伦布: 0.8 %大连: 0.5 %大连: 0.5 %天津: 1.6 %天津: 1.6 %太原: 0.5 %太原: 0.5 %安卡拉: 0.3 %安卡拉: 0.3 %安康: 0.5 %安康: 0.5 %密蘇里城: 0.3 %密蘇里城: 0.3 %布鲁克林区: 0.6 %布鲁克林区: 0.6 %常德: 0.3 %常德: 0.3 %广州: 0.8 %广州: 0.8 %张家口: 4.4 %张家口: 4.4 %徐州: 0.5 %徐州: 0.5 %成都: 0.2 %成都: 0.2 %新加坡: 0.2 %新加坡: 0.2 %无锡: 0.2 %无锡: 0.2 %旧金山: 0.3 %旧金山: 0.3 %昆明: 0.5 %昆明: 0.5 %昭通: 0.2 %昭通: 0.2 %朝阳: 0.2 %朝阳: 0.2 %杭州: 0.2 %杭州: 0.2 %武汉: 1.1 %武汉: 1.1 %沈阳: 0.5 %沈阳: 0.5 %泉州: 0.2 %泉州: 0.2 %法兰克福: 0.3 %法兰克福: 0.3 %波恩: 0.2 %波恩: 0.2 %泰安: 0.2 %泰安: 0.2 %济南: 0.2 %济南: 0.2 %海东: 0.2 %海东: 0.2 %海口: 0.2 %海口: 0.2 %海得拉巴: 0.5 %海得拉巴: 0.5 %深圳: 0.2 %深圳: 0.2 %湖州: 0.3 %湖州: 0.3 %滨州: 0.3 %滨州: 0.3 %玉溪: 0.2 %玉溪: 0.2 %石家庄: 0.2 %石家庄: 0.2 %科泽科德: 0.3 %科泽科德: 0.3 %纽约: 0.3 %纽约: 0.3 %纽约州: 0.2 %纽约州: 0.2 %自贡: 0.2 %自贡: 0.2 %芒廷维尤: 33.5 %芒廷维尤: 33.5 %芜湖: 0.2 %芜湖: 0.2 %芝加哥: 1.3 %芝加哥: 1.3 %苏州: 0.3 %苏州: 0.3 %莫斯科: 0.3 %莫斯科: 0.3 %葵涌: 0.2 %葵涌: 0.2 %西双版纳: 0.5 %西双版纳: 0.5 %西宁: 10.9 %西宁: 10.9 %西安: 0.3 %西安: 0.3 %西雅图: 0.2 %西雅图: 0.2 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.3 %贵阳: 0.3 %赣州: 0.2 %赣州: 0.2 %运城: 0.8 %运城: 0.8 %郑州: 0.8 %郑州: 0.8 %重庆: 0.6 %重庆: 0.6 %铜仁: 0.5 %铜仁: 0.5 %长春: 13.8 %长春: 13.8 %长治: 0.3 %长治: 0.3 %青岛: 0.3 %青岛: 0.3 %黄冈: 0.3 %黄冈: 0.3 %其他LecceTiruchi上海伦敦保定加利福尼亚州北京南京南宁卡纳塔克呼和浩特咸阳哥伦布大连天津太原安卡拉安康密蘇里城布鲁克林区常德广州张家口徐州成都新加坡无锡旧金山昆明昭通朝阳杭州武汉沈阳泉州法兰克福波恩泰安济南海东海口海得拉巴深圳湖州滨州玉溪石家庄科泽科德纽约纽约州自贡芒廷维尤芜湖芝加哥苏州莫斯科葵涌西双版纳西宁西安西雅图诺沃克贵阳赣州运城郑州重庆铜仁长春长治青岛黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (412) PDF downloads(49) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2052]YesterdayPV[3500]TodayIP[2060]TodayPV[4155]Online[205]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return